Apixaban Market Size, Share Report, Analysis, Trends, Growth, 2030

Apixaban Industry Prospective:

The global apixaban market size was evaluated at $11 billion in 2022 and is slated to hit $17 billion by the end of 2030 with a CAGR of nearly 7% between 2023 and 2030.

Request Free Sample

Apixaban Market: Overview

Factor Xa is a serine protease-like trypsin that plays an important role in the cascade of blood coagulation. Apixaban mechanism works on Xa factor inhibiting which indirectly decreases thrombin-stimulated clot formation. Precisely, apixaban is an anticoagulant medicine utilized for treating and preventing blood clots & heart strokes in patients. In addition to this, Apixaban is recommended in patients with non-valvular atrial fibrillation to reduce the risk of stroke or systemic embolism.

Key Insights

• As per the analysis shared by our research analyst, the global apixaban market is projected to expand annually at the annual growth rate of around 7% over the forecast timespan (2023-2030)
• In terms of revenue, the global apixaban market size was evaluated at nearly $11 billion in 2022 and is expected to reach $17 billion by 2030.
• The global apixaban market is anticipated to grow rapidly over the forecast timeline owing to surging breakthroughs in security systems.
• In terms of dosage form, the capsule segment is slated to register the highest CAGR over the analysis period.
• Based on end-user, the hospitals segment is expected to dominate the segmental growth over the assessment timeline.
• Region-wise, the Asia-Pacific apixaban industry is projected to register the fastest CAGR during the assessment timeline.

Apixaban Market: Growth Factors

Growing incidences of venous thromboembolism-related ailments will steer the global market trends

Rise in the occurrence of venous thromboembolism-related ailments will embellish the expansion of the apixaban market across the globe. Furthermore, the growing use of products in comparison to warfarin will further enlarge the scope of the market in the upcoming years. Apart from this, an increase in the cases of atrial fibrillation and stroke in the aging population along with surging incidences of obesity will steer the growth of the global market.

The rapid expansion of healthcare infrastructure along with enhancing healthcare awareness will aid the expansion of the market globally. A prominent surge in the demand for FDA-approved medicines will steer the expansion of the market globally. New drug launches and approvals by statutory healthcare authorities globally can prop up the scope of growth of the global market in the years ahead. For instance, in October 2022, Tiefenbacher Pharmaceuticals, a healthcare & pharmaceutical firm manufacturing generic pharmaceuticals, launched a generic kind of anticoagulant drug referred to as apixaban in Canada. The move will boost the expansion of the global market. In December 2019, the U.S. FDA approved two applications for new apixaban tablets needed for reducing the risk of systemic embolism and stroke in subjects affected by non-valvular atrial fibrillation.

Apixaban Market: Restraints

Adverse drug effects on patients can put brakes on the global industry surge by 2030

Side effects of apixaban including thrombotic events and risks post premature bleeding can put brakes on the global apixaban industry expansion in the upcoming years.

Apixaban Market: Opportunities

Huge government investments in healthcare industry will open new growth avenues for the global market over 2023-2030

Governments are investing massively in research activities related to healthcare, thereby creating new growth opportunities for the global apixaban industry.

Apixaban Market: Challenges

Low access to proper drug treatment in emerging economies can be a key challenge for the industry across the globe

Lack of availability of proper treatments in underdeveloped and developing economies can pose a huge threat to the global apixaban industry. Moreover, few of the patients are required to be treated with new modes of treatment. However, these new therapies are not available in healthcare establishments such as hospitals and ambulatory surgical centers, thereby posing a huge challenge for the global industry.              

Apixaban Market: Segmentation

The global apixaban market is sectored into dosage form, end-user, and region.                

In terms of dosage form, the global apixaban market is segregated into capsule and tablet segments. Furthermore, the capsule segment, which amassed nearly two-thirds of the global market revenue in 2022, is set to record the highest CAGR in the upcoming years. The segmental growth over the assessment timespan can be due to the massive demand for the product in capsule form by patients.

On the basis of end-users, the global apixaban industry is divided into hospitals, online pharmacies, clinics, retail pharmacies, and other segments. Furthermore, the hospitals segment, which amassed a key part of the global industry share in 2022, is slated to lead the global industry over the estimated time interval. The segmental surge over the projected timeframe can be subject to a rise in the use of apixaban in hospitals.

Apixaban Market: Report Scope

Apixaban Market: Regional Insights

North America is prognosis to maintain leadership position in the global apixaban market in the forecasting timeline

North America, which contributed 57% of the global apixaban market revenue in 2022, will be a dominating region over the assessment timeline. Furthermore, the regional market expansion can be subject to a surge in the costs of medicines for venous thromboembolic disease in countries such as Canada and the U.S.  Moreover, the presence of key players in the region will contribute majorly towards the regional market surge.

Asia-Pacific apixaban industry is set to record the fastest CAGR in the ensuing years owing to the presence of strong healthcare infrastructure in the countries such as India and China. In addition to this, supportive healthcare initiatives by governments in these countries will further prompt regional industry growth.

Apixaban Market: Competitive Space

The global apixaban market profiles key players such as:

• F. Hoffmann-La Roche Ltd
• Hikma Pharmaceuticals PLC
• Eisai Co. Ltd
• Sanofi S.A.
• Yino Pharma Limited
• Mylan N.V.
• Bristol Myers Squibb Company
• Abbott Laboratories
• Hebei Changshan Biochemical Pharmaceutical Co. Ltd
• Nanjing Jianyou Biochemical Pharmaceutical Co. Ltd.
• Aspen Holdings
• Fresenius Kabi AG
• Pfizer Inc.

The global apixaban market is segmented as follows:

By Dosage Form

• Capsule
•  Tablet

By End-User

• Hospitals
• Clinics
• Retail Pharmacies
• Online Pharmacies
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa